Niacin therapy unhelpful, occasionally harmful, study says

A combination drug containing niacin failed to lower the risk of heart attacks or strokes and even proved harmful for some with vascular disease, a study released Saturday reported.

Niacin, also known as , has for years been widely prescribed to lower "bad" LDL cholesterol and raise levels of "good" .

The link between high levels of and heart disease is well-documented, and doctors work to mitigate that risk with diet and as well as a variety of medications.

But even with these protocols in place, heart disease and stroke claim lives and cause damage, so scientists continue searching for ways to improve the treatment.

Niacin—in doses about 100 times higher than the recommended amount from food—was thought to be helpful.

Indeed, the used in the study—made by US Merck and combining extended release niacin with laropiprant—is already approved in 70 countries, though not the US.

But when tested against a placebo in more than 25,000 patients, it failed to reduce the numbers of heart attacks, strokes or other serious .

Even more worryingly, the study showed unexpectedly higher levels of bleeding and infections in the group taking the drug versus the placebo.

And the group taking the study drug also showed higher levels of other side effects, including new cases of diabetes and complications for previously-diagnosed diabetes, as well as rashes and diarrhea.

"We are disappointed that these results did not show benefits for our patients", said Jane Armitage, lead author of the study, which included more than 25,000 subjects.

But she and her fellow authors said the result is important, because it gives evidence that the risks of niacin outweigh the benefits when used with current treatments.

Armitage said it was unlikely the poor outcome could be linked to the second component of the drug, laropiprant, which was included to reduce the facial flushing caused by niacin.

The lack of benefit on heart attacks and strokes is consistent with another recent, smaller-scale study of niacin, which did not use laropiprant, and many of the side effects are known to be due to niacin, she explained.

Because of the results of this research, Merck has withdrawn its application for FDA approval of the drug and suspended its sale around the world.

add to favorites email to friend print save as pdf

Related Stories

Merck says cholesterol drug failed to show benefit

Dec 20, 2012

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

Recommended for you

Adrenal sex hormone level may predict heart disease risk

18 hours ago

(HealthDay)—Blood levels of the adrenal sex hormone dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) may predict an increased risk of coronary heart disease (CHD) in elderly men, according to a study ...

Researchers aim to simplify life saving drug

Oct 29, 2014

Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by ...

Frequent readmissions, high costs after cardiac arrest

Oct 29, 2014

(HealthDay)—Frequent readmissions and high inpatient costs are seen among older survivors of in-hospital cardiac arrest, according to a study published online Oct. 28 in Circulation: Cardiovascular Quality an ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.